Vorinostat in Treating Women With Ductal Carcinoma in Situ of the Breast
Status:
Completed
Trial end date:
2015-08-11
Target enrollment:
Participant gender:
Summary
RATIONALE: Vorinostat may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth.
PURPOSE: This clinical trial is studying how well vorinostat works in treating women with
ductal carcinoma in situ of the breast.